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John J. Wilsona, Kin-hoe Chowa, Nathan J. Labriea, Jane A. Brancaa, Thomas J. Sproule a, Bryant R. A. Perkinsa,
Elise E. Wolfa, Mauro Costaa, Grace Stafforda, Christine Rosalesa, Kevin D. Millsb, Derry C. Roopeniana,
and Muneer G. Hashama
aResearch Department, The Jackson Laboratory, Bar Harbor, Maine, USA; bCyteir Therapeutics, Cambridge, MA, USA
ABSTRACT
Targeting the early steps of the glycolysis pathway in cancers is a well-established therapeutic strategy;
however, the doses required to elicit a therapeutic effect on the cancer can be toxic to the patient.
Consequently, numerous preclinical and clinical studies have combined glycolytic blockade with other
therapies. However, most of these other therapies do not specifically target cancer cells, and thus
adversely affect normal tissue. Here we first show that a diverse number of cancer models – sponta-
neous, patient-derived xenografted tumor samples, and xenografted human cancer cells – can be
efficiently targeted by 2-deoxy-D-Glucose (2DG), a well-known glycolytic inhibitor. Next, we tested the
cancer-cell specificity of a therapeutic compound using the MEC1 cell line, a chronic lymphocytic
leukemia (CLL) cell line that expresses activation induced cytidine deaminase (AID). We show that
MEC1 cells, are susceptible to 4,4ʹ-Diisothiocyano-2,2ʹ-stilbenedisulfonic acid (DIDS), a specific RAD51
inhibitor. We then combine 2DG and DIDS, each at a lower dose and demonstrate that this combination
is more efficacious than fludarabine, the current standard- of- care treatment for CLL. This suggests that
the therapeutic blockade of glycolysis together with the therapeutic inhibition of RAD51-dependent
homologous recombination can be a potentially beneficial combination for targeting AID positive
cancer cells with minimal adverse effects on normal tissue.
Implications: Combination therapy targeting glycolysis and specific RAD51 function shows increased
efficacy as compared to standard of care treatments in leukemias.
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Introduction
Glycolysis is a major ATP-producing pathway in mammalian
cells, and can lead to either lactate fermentation or pyruvate
oxidation, with lactate fermentation yielding significantly fewer
ATPmolecules permolecule of glucosemetabolized.1 Cancer cells
are characterized by a high rate of glycolysis as compared to
normal cells, leading to excessive lactate fermentation despite
inefficient ATP production, a phenomenon termed the Warburg
Effect.2–4 This effect was initially thought to be a cause of neo-
plasticity, but now is considered a key feature of neoplastic cells in
numerous types of cancers.5,6 Because of this increased reliance on
glycolysis compared to non-neoplastic cells, glycolytic inhibitors
have been considered an attractive means of targeting cancer.7
However, because glycolysis is a universal metabolic pathway, its
blockade by inhibitors such as 2-deoxy-glucose (2DG) at doses
that are efficacious can yield adverse side effects.8–10 Therefore,
glycolytic inhibitors have been tested at low doses in combination
with other cytotoxic therapies.10 While this combination
approach has been shown to be successful in targeting a number
of malignancies, most compounds used in combination with
glycolytic inhibitors are not tumor-specific and can therefore
damage non-malignant cells.10 In addition, such compounds can
also potentially introduceDNAdamage that can lead tomutations
or breaks, potentially resulting in neomalignancies.10
Consequently, there is increasing consideration of the synergistic
potential of using glycolytic inhibitors in combination with cyto-
toxic chemotherapies administered at doses lower than those used
when such chemotherapies are used alone.More ideally, glycolytic
inhibitors could be therapeutically conjoined with chemothera-
peutic agents that more specifically target the cancer while sparing
normal tissues.
Activation Induced Cytidine Deaminase (AID, AICDA) is
an enzyme that initiates the formation of double-strand
breaks (DSBs) in the heavy chain locus of the immunoglobu-
lin heavy chain locus, a mechanism that leads to antibody
isotype class switching in B-cells.11,12 In addition, AID is also
responsible for somatic hypermutation in the V(D)J locus of
the immunoglobulin genes.13 However, we and others have
shown that AID generates collateral non-immunoglobulin
DNA breaks throughout the genome and that these breaks
can be repaired by XRCC2- and RAD51-dependent homolo-
gous recombination.14–16
A number of B-cell malignancies expresses functional
AID.17,18 In addition, a number of studies have shown that
non-B-cell malignancies also express this enzyme.19–23 It has
been hypothesized that the presence of AID assists in enhan-
cing the generation of somatic mutations of the cancer gen-
ome, resulting in increased survival and/or propagation of the
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cancer.18,22,24,25 We previously identified a small-molecule
RAD51-specific inhibitor, 4,4ʹ-Diisothiocyano-2,2ʹ-stilbenedi-
sulfonic acid (DIDS), that specifically disrupts the repair of
AID-induced breaks in primary and neoplastic mouse B-cells
and inhibits the growth of AID-positive human CLL cancers
ex vivo.17 The effect of DIDS in vivo was strain-dependent: In
C57BL/6J mice DIDS significantly reduced the number of
post-germinal B-cells; however, in the autoimmune strain
NOD/ShiLtDvs, DIDS significantly increased the number of
autoregulatory CD73 + B-cells and suppressed Type I
diabetes.17,26 These strain-dependent differences in response
to DIDS suggest a complex role for RAD51 inhibition in
B-cells.
Here we investigate the potential of a glycolytic inhibitor,
2DG, to alleviate tumor burden in spontaneous and patient-
derived xenograft (PDX) cancer mouse models. Furthermore,
we show that DIDS can reduce tumor burden in xenografted
cell lines in vivo. Ultimately, we observe that the efficacy of
DIDS in reducing tumor burden in vivo in mice can be
enhanced by the effect of 2DG, both used at dosages that
lower the risk of adverse effects, indicating that the combina-
tion of RAD51 inhibition and glycolytic blockage can be a
potentially effective therapy against AID-positive cancers.
Results
2DG alleviates tumor burden in a spontaneous mouse
model of lymphomagenesis
SJL/J mice spontaneously develop a hyperplastic disorder
involving CD4 + T-cells and B-cells that resembles non-
Hodgkin lymphoma and is evident after one year of age.27,28
It is thought that activated CD4+ T-cells secreting interleukin
21 drive B-cells to transformation in this model.29 SJL/J mice
deficient in CD8a and thus lacking CD8 + T-cells show sig-
nificantly accelerated development of B-cell lymphomas, with
no change in other aspects of their phenotype.30 Since the
growth or maintenance of any tumor requires energy, and
highly proliferative cells such as cancer cells depend on
numerous modes of ATP production, including glycolysis, to
meet their energetic demands, blocking glycolysis in cancer
cells at the first steps following cellular glucose intake should,
in theory, reduce tumor burden.4,6,7 To test the extent to
which inhibition of glycolysis by 2DG can alleviate these
spontaneously arising lymphomas, we first aged a cohort of
SJL.CD8a-/- female mice to 13 months of age and monitored
them for signs of lymphoma development. Visible growth was
most evident in cervical lymph nodes and in some cases in
spleens (indicated by arrows, Figure 1A). Once tumors were
sufficiently large to palpate, mice were placed on water with
6 g/L of dissolved 2DG provided ad libitum. The average
mouse consumed approximately 4 ml of water each day;
hence, based on the average weight of the mice, each mouse
received a dose of 2DG of approximately 900 mg/kg/day.
Photographs of the tumors were taken weekly to document
disease regression, and the time points, in weeks, at which the
tumors visibly shrank or, later, reemerged, were recorded. Via
gross observation of the mice, we observed no adverse side
effects of this treatment, such as weight loss, lethargy, or lack
of grooming, either shortly after treatment initiation, or at any
time during the treatment.
Of the seven mice in this study, six showed evidence of
tumor regression after two or three weeks of treatment
(Figure 1A and B). However, in four of these six, the tumors
returned within 5–11 weeks, despite continuation of the treat-
ment. This significant regression, which is similar to what is
observed in mouse models of solid cancer treated with 2DG
(see ref. 10), suggested that SJL lymphomas are partially
responsive to relatively high therapeutic doses of a combina-
tion treatment for lymphoid cancers.
We wanted to extend the above findings by testing a more
homogeneous and acute spontaneously arising lymphoma. In
addition, we wanted to test the extent to which 2DG could
affect a purely T-cell lymphoma. To meet all of these criteria,
we turned to a classic mouse model of T-cell cancer, the p53-
deficient mouse.31 The Trp53 gene codes for the p53 protein,
and deficiency of this gene in mice leads to thymic lympho-
mas as early as 14 weeks of age (Figure 1C; Supplementary
Figure 1); because of this phenotype, the Trp53-/- mouse is
considered a model of Li-Fraumeni Syndrome {Jacks, 1994
#134}. To test the effect of 2DG on these thymic lymphomas,
B6.Trp53-/- mice were treated with either 2DG (200 µL of
2DG at 600 mM in DPBS (670 mg/kg)) or glucose, intraper-
itoneally (I.P.) three times weekly, starting at 14 weeks of age
and continuing for 10 weeks. We observed that mice treated
with 2DG were significantly protected (Log rank Mantel Cox
test P = .04 and Gehan-Breslow-Wilcoxon test p = .05) from
developing neoplasms compared to glucose-treated mice
(Figure 1D). Two notable adverse effects were observed with
2DG treatment delivered I.P.: first, upon injection, 2DG-trea-
ted mice showed inactivity for 10–60 minutes, and, second, as
the experiment progressed, the 2DG-treated mice showed
lower weight gain compared to glucose-treated mice, although
the difference did not achieve significance (Figure 1E).
Together, based on two different mouse models of sponta-
neous cancer, 2DG administered orally or I.P. can alleviate
both B- and T-cell tumor burdens; however, in the latter case,
treatment resulted in notable adverse effects.
Lung tumor PDX models indicate that metabolic
differences and not proliferation determine susceptibility
to 2DG
We then sought to eventuate the effects of 2DG in human
lung carcinoma PDX (patient-derived xenograft) models.
While it is understood that 2DG primarily affects glycolysis,
studies have shown that 2DG can interfere with other systems,
such as the cell cycle, independently of its effects on
metabolism.8,32,33 Changes in the cell cycle would affect the
proliferation of cancer cells, ultimately influencing tumor
growth. To test whether 2DG affects glycolysis independently
of proliferation, we tested two PDX human lung carcinomas
(TM00244 and TM00921) with similar growth kinetics
(Figure 2A) but differing in the use of glycolytic pathways
(Table 1; Supplementary Table 1; Supplementary Figure 2).
Both of these PDX tumors are from the primary malignancy
lung squamous cell carcinoma Grade 2. TM00244 is from a
62-year old white female and TM00921 is from a 66-year old
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Figure 1. 2-deoxy-D-Glucose (2DG) alleviates tumor burden in a spontaneousmouse cancermodel. (A) Representative images showing inguinal lymphnode tumor reduction on
an SJL mouse treated with 2DG dissolved in drinking water (6 g/L). (B) Chart showing the transient effect of 2DG on tumor regression, and subsequent re-emergence (N = 7). (C)
Computed tomography (CT) scans of a p53wildtype (Trp53+/+) and p53mutant (Trp53-/-)mouse, showing themaximum engulfment of a thymic lymphoma in the chest cavity.
(D) Survival curve of Trp53-/-mice treatedwith2DG (670mg/kg) or glucose (control) three times perweek via intraperitoneal injections. (E)Weights ofmice during glucose or 2DG
treatment.
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American Indian or Alaskan male. A direct comparison of
overall gene expression between the two carcinomas reveals
that one carcinoma, TM00244, shows transcripts for alterna-
tive metabolic pathways as compared to the TM00921 carci-
noma (Table 1; Supplementary Table 1; Supplementary
Figure 2). We xenografted tumors from these two carcinomas
into immunodeficient NOD.Scid.IL2R gamma null (NSGTM)
mice, and, after tumors of a measurable size (> 50mm3) were
observed, we treated mice of each model with 200 µL of either
600 mM 2DG or glucose three times weekly via I.P. injection.
After 4 weeks of treatment, TM00921-xenografted mice
showed a significantly smaller tumor volume with 2DG treat-
ment compared to glucose treatment, whereas TM00244-
xenografted mice showed no difference in tumor size between
2DG and glucose-treated mice (Figure 2B). Several genes that
allow the utilization of other forms of metabolism or path-
ways that feed into the glycolysis pathway downstream of
hexokinase are overexpressed in the resistant TM00244
tumor as compared to the susceptible TM00921 tumor
(Supplementary Table 1), suggesting that inherent differences
in metabolic pathway use – i.e., reliance on glycolysis or not –
may impact tumor responses to 2DG.
Table 1. Pathway differences between TM00921 and TM00244 (INGENUITY/KEGG PATHWAY).
Pathway Number of genes p-Value
Metabolic pathways 11 6.6E-2
Arachidonic acid metabolism 4 3.4E-3
Drug metabolism-cytochrome P450 4 4.4E-3
Metabolism of xenobiotics by cytochrome P450 4 5.6E-3
Tyrosine metabolism 3 1.3E-2
Glutathione metabolism 3 2.6E-2
Chemical carcinogenesis 3 5.9E-2
Toll-like receptor signaling pathway 3 9.5E-2
Phenylalanine metabolism 2 8.1E-2
Figure 2. Glycolysis sensitivity rather than proliferation determines susceptibility to 2DG in lung PDX tumor models. (A) Glycolysis-dependent (TM00921) and
glycolysis-independent (TM00244) PDX lung tumors were subcutaneously xenografted in NSGTM mice, and tumor growth was measured for 4 weeks. Growth was
normalized to the initial size of the tumor for each individual mouse (N = 4–5) and plotted as fold increase. (B) Growth of the two lung tumors in mice treated with
either 2DG or glucose (control).
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Glycolysis-dependent B-cell cancers are sensitive to 2DG
While the above experiments using PDX models give a strong
indication that lung tumors relying on glycolysis will be
susceptible to 2DG therapy, the heterogeneity of PDX tumors
can be a confounding variable, as each PDX tumor contains
multiple cell types with different glycolytic demands.34,35 To
control for this cellular heterogeneity, and to extend our
findings to human B-cell cancers, we screened B-cell cancer
cell lines and obtained two lines, CCRF-SB and MEC1, that
share similar aerobic respiration rates but differ in their use of
glycolysis as a source of energy (Figure 3A), and yet have
similar proliferation rates ex vivo (Figure 3B).36,37 These data
allow us to hypothesize that MEC1 cells, which are more
glycolysis-dependent than are CCRF-SB cells, will be more
sensitive to 2DG. To test that hypothesis, the two cell lines
were tested for 2DG sensitivity in vivo: immunodeficient
Figure 3. The glycolysis-dependent MEC1 cell line is susceptible to 2DG in vivo. (A) Metabolic comparison of two AID-positive B-cell lines, MEC1 and CCRF-SB with (B)
similar growth rates ex vivo (N = 3 in two experiments). (C) Graphs showing bone marrow and spleen tumor burden as measured by human CD19+ cells (N = 4 mice).
(D) Comparison of free glucose inside spleen and bone marrow cells of mice treated with 2DG or Glucose (6 g/L) or regular water (vehicle) for 1 week (N = 5 Mice per
group).
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NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRGTM) mice were
xenografted with either MEC1 or CCRF-SB cells, and the
mice were then treated with 200 µL of 600 mM 2DG or
glucose I.P. three times per week for two weeks. Both MEC1
and CCRF-SB cells migrate to the spleen and bone marrow,
and since these mice express CD19 + B-cells, the tumor
burden can be measured in these organs by anti-human
CD19 staining via flow cytometry after euthanasia at the end
of the treatment period. In contrast to CCRF-SB cells, which
showed no significant response to 2DG in spleens or bone
marrow, MEC1 cells in the bone marrow showed significant
reductions in numbers with 2DG treatment (Figure 3C).
Interestingly, while MEC1 cells in the bone marrow showed
sensitivity to 2DG, those in the spleen did not (Figure 3C).
To further investigate this disparity, we determined the
cellular concentrations of free glucose in spleens and bone
marrow of NRGTM mice treated for 1 week with 2DG or
glucose in drinking water at 6 g/L or water with no addi-
tives provided ad libitum. We found only a trending drop
(P = .056) of free glucose in spleen cells from 2DG treated
compared to glucose treated mice (Figure 3D). In contrast
there was a significant increase in free glucose in the bone
marrow of 2DG treated compared to glucose or vehicle
treated mice (Figure 3D). We hypothesize that bone mar-
row cells are more proliferative and, due to this increased
activity, they take up more 2DG that blocks the glycolysis
pathway; this leads to a subsequent increase in the unused
glucose levels in the bone marrow cells. This would mean
that MEC1 cells that home to the bone marrow as opposed
to the spleen are more prolific and are therefore more
affected by glycolytic blockade. This result indicates that
there are organ-specific differences in the response of
MEC1 cells to 2DG. Overall, the results suggest that glyco-
lysis-dependent B-cell cancers are more sensitive than gly-
colysis-independent B-cell cancers to 2DG, with the proviso
that MEC1 cells in different sites may also differ in their
sensitivity to 2DG.
The RAD51 inhibitor DIDS reduces the splenic tumor
burden of a chronic lymphocytic leukemia (CLL)
xenografted cell line
As noted above, AID generates immunoglobulin locus-inde-
pendent DNA breaks throughout the genome that are
repaired by XRCC2- and RAD51-dependent homologous
recombination.15,16 It was previously shown that DIDS could
specifically target AID-positive neoplastic cell lines in tissue
culture.17 Importantly, DIDS also targeted AID-positive, but
not AID-negative, human CLL cells from patients ex vivo.17
We wanted to test the extent to which DIDS could target a
xenografted AID-positive CLL cell line in vivo. We utilized the
glycolytic MEC1 B-cell line, which can be quantified by CD19
expression ex vivo.36 We first confirmed AID positivity of
MEC1 B-cells, using reverse transcriptase (RT)-PCR, and
then compared AID expression of MEC1 B-cells with that of
K562 cells, an AID-deficient cell line, and of CCRF-SB, an
AID-positive ALL cell line. To control for the amount of RNA
input, the samples were also tested for the control gene
Gapdh. Results show that MEC1 B-cells constitutively express
AID (Figure 4A). AID was also detected by intracellular stain-
ing of AID and flow cytometry (Figure 4B). We then pro-
ceeded to test the sensitivity of MEC1 B-cells to DIDS ex vivo.
DIDS was titrated from 0 to 0.2 mM, with 2 × 105 MEC1
B-cells. Cytotoxic effects of DIDS on MEC1 B-cells were seen
as early as 5 days at 0.05 mM, and a significant effect was
observed with doses at 0.1 and 0.2 mM after 5 days
(Figure 4C).
Because DIDS was effective in reducing numbers of
MEC1 B-cells ex vivo, we wanted to test its effectiveness
in vivo. To accomplish this, 2 × 107 MEC1 cells were
xenografted into immunodeficient NRGTM mice for two
weeks, and mice were then treated either with DIDS at
50 mg/kg or with a 0.1 M potassium bicarbonate/PBS
vehicle, once per week for an additional two weeks. We
used NRGTM mice because they are deficient in CD19 cells,
allowing us to quantify MEC1 B-cells by staining spleen
cells for human CD19, as the spleen is a homing organ for
MEC1 B-cells, all of which are positive for CD19. We
observed that, despite the wide range of xenograft capabil-
ities among the tested mice, 10 of 11 mice treated with
DIDS showed a significant (p = 0.001) reduction in the
number of MEC1 cells in the spleen (Figure 4D).
The therapeutic effect of DIDS on MEC1 cells requires AID
To directly determine if the effect of DIDS was dependent on
AID, we generated three CRISPR guides that targeted exon 2
of AID (Supplementary Figure 3A). This exon was targeted
because it is the first exon sufficiently large for the efficient
design of CRISPR guides. The guides were transfected into
MEC1 cells, and the cells were cloned by limiting dilution.
One clone (Clone #14) that grew at a rate similar to the
parental cell line, MEC1 was divided into four subclones
(Clones #14–1, 14–3, 14–14 and 14–15). Upon sequencing,
it was discovered that they all had a 25-base pair deletion in
exon 2 of one allele and a complete deletion of exon 2 on the
other (Supplementary Figure 3A and 3B). Theoretically, this
would result in a truncated, non-functional AID, which we
termed AID knockout MEC1 (AKO) cells. To test the depen-
dence of DIDS on AID, we treated AKO cells with DIDS and
compared their growth with that of parental MEC1 cells. The
impact of DIDS on the proliferation of AKO cells was sig-
nificantly different than its impact on proliferation of parental
MEC1 cells (Supplementary Figure 3C). Moreover, unlike the
parental MEC1 cells, AKO cells grew at a similar rate regard-
less of whether the cells were treated with vehicle or DIDS
(Supplementary Figure 3C). To test whether AID sufficiency
was required for DIDS efficacy in vivo, we xenografted AKO
and parental cells in NRGTM mice, and treated the mice with
50 mg/kg of DIDS for two weeks. Compared to parental
xenografted MEC1 cells, AKO cells were more resistant to
DIDS as measured by the percentages of human CD19 cells
(Figure 4E) and by spleen weights (Supplementary
Figure 3D). Thus, the therapeutic effect of DIDS in MEC1
xenografts depends on AID.
The results above indicate that DIDS affects AID-initiated
breaks in vivo. We next sought to determine whether DIDS
could block repair of AID-independent double-strand breaks
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(frank or single-strand staggered double-strand breaks) in
vivo. A common way to generate double-strand breaks is via
ionizing radiation (IR).1,38,39 For this, we treated AID-null
mice with different concentrations of DIDS (0, 5, or 10 mg/
kg) for eight hours, and then harvested splenocytes and trea-
ted them with different doses of IR (0, 1, 5, 10 Gy). Eighteen
hours after IR, the numbers of live white blood cells (CD45
+ Ter119- PI-) were measured by flow cytometry. Results
showed that IR alone results in decreased survival of the
cells; however, in the presence of DIDS, the effect is signifi-
cantly greater (Figure 4F). This effect is particularly evident at
10 Gy when the cell data are normalized to the 0 mg/Kg
DIDS-treated data, where even a tenth of the dose of DIDS
can synergistically enhance the severity of cell ablation
(Figure 4F). These data indicate, that while DIDS can block
repair of AID-initiated DSBs, it can also block repair of IR-
induced DSBs. Importantly, the results indicate that DIDS, or
any RAD51 inhibitor, has the potential to be paired with
ionizing radiation to enhance the therapeutic effect of the IR
alone.
Rapid synergistic effect of glycolytic blockade and
RAD51 inhibition on MEC1 cells ex vivo and in vivo
Having found that RAD51 inhibition by DIDS can be
improved by adjunct therapy such as radiation, we sought to
test whether the combined use of DIDS and 2DG would have
a synergistic effect on AID-positive neoplasms, both in vitro
and in vivo. We reasoned that RAD51 function requires ATP
and that, therefore, a reduction in the pool of ATP should
Figure 4. The RAD51-sensitive MEC1 cell line can be targeted by the RAD51 inhibitor DIDS in vivo. (A) Quantitative RT-PCR of AICDA (AID) and RAD51 of MEC1, K562,
and CCRF-SB cells. (B) Flow cytometry of intracellular staining of AID in the aforementioned cell lines. (C) Ex vivo growth of MEC1 B-cells in the presence of different
doses of DIDS. (D) MEC1 tumor burden in NRG™ mice after two-week treatment with DIDS as measured by hCD19+ cells in the spleen. Each point represents a mouse
(data pooled from 3 experiments). (E) Tumor burden of MEC1 cells and MEC1 cells without AID (AKO) after DIDS treatment (N = 5 to 9 mice). (F) In vivo treatment of
AID-/- mice with different concentrations of DIDS, followed by treatment of splenocytes with radiation ex vivo, illustrating the capacity of DIDS to work in
combination treatment with IR (N = 5 mice).
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decrease the efficiency of RAD51-dependent repair and
enhance the cytotoxic effect of DIDS on rapidly proliferating
AID+ neoplastic cells (Supplementary Figure 4).39,40 To test
this possibility, we titrated 2DG with DIDS on MEC1 cells,
since MEC1 cells are sensitive to both 2DG and DIDS. By day
2 there was a reduction of cell numbers as the concentration
of DIDS was increased (Figure 5A), consistent with our earlier
results (Figure 4C). However, the addition of 0.2 mM of 2DG,
a concentration that does not have an effect on its own (y-
axis, Figure 5A), enhanced the cytotoxic effect of DIDS
(Figure 5A). From the slopes of the titration, it can be sur-
mised that 2DG has a synergistic effect with DIDS, not only
with respect to the lower concentrations of DIDS required to
elicit an effect, but also kinetically, since we see the effects by
48 hours, in contrast to 5 days (Figure 5A versus Figure 4C).
In order to determine the extent to which this 2DG-mediated
synergistic effect holds for any AID-positive cell treated with
any RAD51 inhibitor, we used a different RAD51 inhibitor,
B02 (Sigma), on MEC1 and on another AID positive cell line,
SuDHL. In addition, we also tested DIDS on SuDHL cells. In
each experiment, we combined RAD51-inhibitor treatment
(B02 or DIDS) with 2DG treatment. Together, results of the
two experiments and our earlier experiment treating MEC1
cells with DIDS and 2DG (Figure 5A) show that treatment of
either of two AID-positive cell lines with 2DG has a similar
synergistic effect on the efficacy of two different RAD51
inhibitors (Figure 5B, Supplementary Figure 4). Importantly,
the results also suggest that the combination of 2DG with any
RAD51 inhibitor will have a synergistic therapeutic effect on
any AID-positive cancer.
To test whether this synergistic effect at low doses can be
recapitulated in vivo, MEC1-xenografted mice were treated
with DIDS alone, 2DG alone, or DIDS and 2DG in combina-
tion, all at low concentrations, or with a positive or negative
control. Mice were treated I.P. three times weekly for two
weeks. 1) Mice were dosed I.P. with 10 mg/kg DIDS, a fifth of
the dose required to elicit an effect in vivo (Figure 4D); 2)
mice were treated I.P. with 220 mg/kg of 2DG or glucose; a
third of the dose of 2DG required for an effect (Figure 3C); 3)
mice were treated with both DIDS and 2DG, at the same
doses used in the first two groups; 4) as a positive control,
mice were treated with fludarabine, a compound frequently
used to treat CLL, at 35 mg/kg, a dose commonly used to elicit
an effect; and 5) as a negative control, mice were treated with
vehicle consisting of glucose in PBS.41 Following the 2-week
treatment period, bone marrow and spleens were assessed for
tumor burden, by determining the percentages of human
CD19-positive cells via flow cytometry (Figure 5C).
In the bone marrow (Figure 5C), the combination DIDS/
2DG treatment resulted in a significant (p < 0.002) decrease in
tumor burden compared to vehicle, and also a decrease com-
pared to treatment with fludarabine, although this decrease
was not statistically significant (p = 0.26). Interestingly, in the
bone marrow, 2DG alone elicited as much effect as the com-
bination treatment (Figure 5C). In the spleen, the combina-
tion treatment produced the best outcome compared to either
compound separately or vehicle (p = 0.001), and even per-
formed significantly better than fludarabine (p = 0.03)
(Figure 5C). Together, these data suggest that a combination
RAD51-inhibitor/glycolysis-inhibitor treatment at lower doses
is more effective in treating MEC1 cells in vivo than the
current standard of treatment, fludarabine. Furthermore, at
these reduced doses of DIDS and 2DG, the adverse effects of
these treatments, including change in weight, were not
observed, as at the end of the treatment regime the weights
of the treated mice were similar to those of the untreated or
vehicle-treated mice (Figure 5D). To test for a mechanism of
the observed synergy, we exposed MEC1 cells for 24 hours to
various concentrations of 2DG and measured intracellular
ATP levels. This revealed a dose dependent decrease
(R2 = .9296) in intracellular ATP as 2DG doses increase
(Figure 5E). The reduced ATP pool should further inhibit
ATP dependent RAD51 function and augment the cytotoxic
effects of DIDS. Together, these results indicate that 2DG, in
combination with the RAD51 inhibitor DIDS, can be admi-
nistered safely at reduced doses of each compound to produce
a cytotoxic effect on the cancer that is more effective com-
pared to treatment with DIDS alone, while eliciting no evi-
dence for adverse effects, which is the best outcome for the
treatment of any disease.
Discussion
Glycolysis is a primary energy source for all cells. The concept
of blocking glycolysis to prevent the expansion of cancer cells
is well established.3,4,6,10 It has been known for decades that a
number of cancer-cell types require a high rate of glycolysis
compared to normal cells (the Warburg Effect) that favors
lactate fermentation rather than aerobic respiration.3,4
However, since both pathways begin with glycolysis, thera-
peutic targeting of early steps in glycolysis poses a challenge
with respect to specificity. Moreover, cancers can adapt to the
therapeutic and/or favor the growth of cells whose glycolytic
demands are lower than those of typical cancer cells and
therefore do not require the targeted pathway.42,43
Therefore, targeting the glycolytic pathway has the potential
not only to directly interfere with normal cell metabolism but
also to provide selection pressure for tumors to adapt to
sources of energy other than glucose. For these reasons, a
number of pre-clinical studies and clinical trials combine
glycolysis blockade with other chemotherapies.10 In several
of these, the total dose of combined chemotherapy required
to elicit a favorable therapeutic outcome was significantly less
than the dose required for either therapy alone.6,10
Here we first show that 2DG monotherapy administered at
high doses can be efficacious in treating two different sponta-
neous mouse models of lymphoma: the SJL/J model of non-
Hodgkin lymphoma and the B6.Trp53-/- model of T-cell
lymphoma. Furthermore, we show that high doses of 2DG
show greater efficacy in glycolysis-dependent human PDX
lung cancers and B-cell line lymphoma xenografts than they
do in those that are not strictly reliant on glycolysis10.
Together, these findings support the concept that glycolysis-
dependent tumors can be targeted by 2DG. However, the high
dose of 2DG required to elicit an effect, combined with the
transience of the tumor reduction/resistance (Figure 1A, B),
suggest that 2DG is not suitable as a stand-alone lymphoma
therapy. Synergistic efficacy has been described when
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Figure 5. Glycolysis blockade and RAD51 inhibition exhibits a synergistic and enhanced anti-cancer effect on tumor burden. (A) Ex vivo intracellular ATP levels in MEC1 cells
incubated with different doses of DIDS and 2DG 48 hours after incubation. (B) Heat map of the proliferation of MEC1 and SuDHL cells treated with 2DG or DIDS ex vivo. The color
shows the numbers (in millions) of cells after 5 days of proliferation. Initial number for MEC1 was 1million cells and SuDHLwas 0.5 million cells. (C) In vivoMEC1 tumor burden as
measured by the percentage of hCD19+ cells in the spleen and bone marrow after two-week treatment with low doses of DIDS and/or 2DG, with fludarabine, or with glucose
(N= 4–13mice in twoexperiments). (D) Averageweight of themice in each group at theend of the treatment regimen. (E) Ex vivo intracellular ATP ofMEC1 cells incubated in 2DG
at varying concentrations for 24 hours (N = 3).
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glycolysis inhibition by 2DG is combined with conventional,
non-specific, anti-cancer therapies that target basic functions
such as DNA replication, cell cycle or transcription.10 2DG,
even at reduced dosages as is the norm in combination thera-
pies, combined with compounds that more specifically target
cancer cells, may result in safer and more effective combina-
tion therapies with fewer off-target effects.
Previously, we showed that the RAD51 inhibitor DIDS can
specifically target AID-positive but not AID-negative primary or
neoplastic cells ex vivo.17 Herein, we show that DIDS has a
therapeutic effect in vivo specifically on AID-positive cells.
While DIDS itself is not clinically translatable due to its chemical
composition, the concept of using a RAD51 inhibitor to speci-
fically target AID-positive and not AID-negative cells – as we
have now shown is possible using in vivo xenograft models –
allows the clinical development of a RAD51 inhibitor that could
be used as a chemotherapeutic targeting the AID-RAD51 path-
way. Furthermore, while it can be argued that RAD51-depen-
dent repair is a universal double-strand break repair mechanism,
we have not observed adverse effects of a RAD51 inhibitor on
any AID-negative cells or any mouse models treated with DIDS,
either in the present study or previous studies.17,44,45 The only
reported adverse effect of DIDS treatment was in C57BL/6J
mice, which showed a reduction in the percentage of AID-
positive post-germinal B-cells following DIDS treatment; how-
ever, this effect was not observed in NOD mice, where DIDS
increased the number of CD73 + B-cells, while suppressing the
autoimmune disease.17,26,46,47 Therefore, targeting AID-positive
cancers could potentially target mature class-switching B-cells
should stable derivatives of DIDS be available for human treat-
ment, and the effect could be potentially overridden by immu-
noglobulin transfusions in the clinic.
In the current study, we found that in SJL.CD8a-/- mice,
even when treated with 2DG for 11 weeks, did not result in
observable adverse effects, while B6.Trp53-/- mice showed a
transient adverse effect with 2DG administration. We com-
bined the specific inhibition of RAD51, via DIDS, with the
generalized anti-glycolytic effect of 2DG, each at a lower dose
than is used when the compound is administered alone, with
the overall goal of narrowing the specificity of an anti-glyco-
lytic inhibitor such that it impacts only cancer cells. While it is
true that this therapy would be limited to AID-positive can-
cers, this study is proof-of-concept that simultaneous inhibi-
tion of glycolysis and RAD51-dependent repair can augment
the synthetic lethal effect specifically on AID+ cancers. As
published previously, about half of all CLLs express AID,
and a number of publications show the expression of AID
in non-lymphoid tumors, presenting the possibility that this
therapy could potentially be used for non-lymphoid
cancers.17,18,20,21,23
The observation that the combination of both glycolytic
blockade and RAD51 inhibition leads to enhanced efficacy
against tumorigenesis can be explained in two ways: First,
ATP is required for multiple processes other than repair.
Thus, reducing glycolysis by 2DG (Figure 5E) weakens the
cancer cell, regardless of the action of DIDS. This was
observed in the bone marrow in the MEC1 cell-xenografted
study where there was no difference in the tumor burden with
or without DIDS. Second, in the spleen, the presence of DIDS
made a significant difference, and the two compounds showed
a synergistic effect.
Lastly, we also observe that simultaneous blocking of gly-
colysis, with 2DG, and inhibition of RAD51, with DIDS, not
only has a synergistic effect, but also results in a substantially
more rapid effect compared to the use of DIDS alone. This
advantage could be translated into a shorter treatment time
for chemotherapy, which could lead to less severe adverse
effects, lower costs, and a smaller chance that a tumor will
develop resistance against the treatment.
In summary, we show that combining glycolytic blockade
using 2DG, and RAD51 inhibition using DIDS, each at lower
doses compared to solo administered, can synergistically
reduce the numbers of AID-positive cancer cells both ex vivo
and in vivo. While only AID-positive cancer cells are targeted
in this study, our results suggest that this approach could be
used with tumors that are not AID-positive, as RAD51 is used
to repair fork collapses in rapidly replicating cells as well as to
repair double-strand breaks.48,49 Furthermore, while AID has
been implicated as a tumor-promoting gene in a number of
cancers, a modification of our combination therapy approach
could potentially be effective in homologous recombination-
negative cancers such as BRCA mutants, in which AID is
unlikely to play a tumorigenic role.50 Specifically, patients
could be administered recombinant AID and 2DG simulta-
neously. This could potentially result in a lethal combination
in the cancer cell through administration of a clastogenic pro-
tein – AID – together with the creation of conditions for
reduced levels of homologous recombination via depletion of
the ATP pool. This combination could expand application of
the therapy concept discussed herein to AID-negative cancers.
Taken together, we have provided proof-of-concept that the
combination of AID, RAD51 inhibition, and glycolysis block-
ade can be a beneficial combination for treating cancers while
minimizing the potential for adverse effects, due to the cell
specificity and kinetics, and the lower doses required to elicit
a lethal effect on cancer cells.
Materials and methods
Mice
C57BL/6J (JR664, JAX), B6.129S2-Trp53tm1Tyj/J (B6.Trp53-/-,
JR2101, JAX), NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRGTM,
JR7799, JAX), NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSGTM,
JR5557, JAX), and SJL.129S2(B6)-Cd8atm1Mak/1Dcr (SJL.
Cd8a-/- JR4023, private strain: Derry Roopenian) mice used
in this study were bred and housed at The Jackson Laboratory
(Bar Harbor, Maine). Mice were provided with food and
water ad libitum and were housed on a 14-hour light, 10-
hour dark cycle. All procedures were approved by The
Jackson Laboratory Institutional Animal Care and Use
Committee (IACUC).
Cells
Human peripheral blood acute B-lymphoblastic leukemia cells
(the CCRF-SB cell line (ATCC)); human chronic lymphocytic
leukemia cells (the MEC1 cell line (Cat. no. ACC 497,
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DSMZ)); AID-positive peritoneal effusion B-lymphoblast
SUDHL-4 cells (a gift from Cyteir Therapeutics); and K562
myeloid leukemia cells (a gift from Dr. Jennifer Trowbridge,
The Jackson Laboratory) were cultured according to manu-
facturer’s/donor’s recommendations. Cell viability counts
were done on the Countess II Automated Cell Counter
(Invitrogen) according to manufacturer’s recommendations.
Generation of AID KO MEC1 cell line
AID knockout (AKO) MEC1 cell lines were developed by
targeting Exon 2 of AID with the following guide RNAs:
CTTGATGAACCGGAGGAAG, GTCCGCTGGGCTAAGGG
TC, GTGCTACATCCTTTTCAC. These guides were cloned
into the Cas9-EGFP vector, pX330 (Addgene, Cat. no. 66582).
These vectors were nucleofected into MEC1 cells using
Amaxa Cell Line Nucleofector Kit V using program X-001,
and according to manufacturer’s instructions (Lonza, Cat. no.
VACA-1003). Nucleofected cells were sorted for GFP positiv-
ity and cloned by limited dilution to generate AKO cell lines.
Two independent AKO cell lines (14–1 and 14–3) were con-
firmed for AID nullizygosity using both genomic and tran-
script PCRs.
Compounds
2-deoxy-D-glucose (Cat. no. D8375), the RAD51 inhibitor
B02 (Cat. no. SML0364), and fludarabine phosphate (Cat.
no. 1272204) were obtained from Sigma-Aldrich. DIDS was
obtained from ChemCruz (Cat. no. sc-203919).
Quantification of AID and RAD51
Total RNA was extracted from tissue samples using the
RNeasy Mini Kit according to manufacturer’s protocol
(QIAGEN, Cat. no. 74104). In order to detect AID and
RAD51 by qPCR, 1% β-mercaptoethanol in Buffer RLT was
added to the tissue at a ratio of 100 mg/1.25 mL. Synthesis of
cDNA was done using the RT2 First Strand Kit following
manufacturer’s protocol (QIAGEN, Cat. no. 330404). 500 ng
of RNA was used when available; otherwise, the next-largest
amount of RNA for the set of samples was used. For qPCR,
oligonucleotides to detect GAPDH transcripts were 5ʹ-
GAGTCAACGGATTTGGTCGT-3ʹ (forward) and 5ʹ-TTG
ATTTTGGAGGGATCTGC-3ʹ (reverse). Oligonucleotides to
detect AICDA transcripts were 5ʹ-TTCTTTTCAC
TGGACTTTGG-3ʹ (forward) and 5ʹ-GACTGAGGTTGG
GGTTCC-3ʹ (reverse). Oligonucleotides to detect RAD51
transcripts were 5ʹ-CAACCCATTTCACGGTTAGAGC-3ʹ
(forward) and 5ʹ-TTCTTTGGCGCATAGGCAACA-3ʹ
(reverse). For each sample, three 25 µL reactions were run
of varying cDNA concentrations (10, 5, and 1 µL). The reac-
tions were run on an Applied Biosystem Model 7500 thermo-
cycler using RT2 SYBR Green ROX qPCR Mastermix
(QIAGEN, Cat. no. 330520). PCR conditions were 50°C for
2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s,
60°C 1 min.
To detect AID by flow cytometry, cells were fixed in 3%
Neutral Buffered Formalin (Cat. no. MER 44991 GL,
Mercedes Chemicals), 2% sucrose (Cat. no. S8501 Sigma-
Aldrich) in DPBS (Cat. no. 14190250, ThermoFisher) at a
concentration of one million per mL for 10 minutes in sus-
pension at room temperature. The cells were then washed
with DPBS by centrifugation (400 x g x 5 mins) and permea-
bilized with 0.1% Triton-X-100 (Cat. no. X100, Sigma-
Aldrich) in DPBS, and washed once with DPBS. The cells
were then incubated with 1 mL of 10% FBS in DPBS for 1
hour, and stained overnight at 4°C with anti-AID antibody
(ab93596, Abcam) at 1:100 in 0.1 mL, 10% FBS in DPBS. The
cells were washed twice with DPBS, and incubated with a
1:1,000 dilution of Alexa 488 goat anti rabbit IgG (Cat. no.
A27016, ThermoFisher) in 0.1 mL of 10% FBS in DPBS for 1
hour at room temperature in the dark. The cells were washed
twice with DPBS, and data were acquired using a FACScaliber
II and were analyzed by FlowJo Version 8.8.7.
PDX xenografts and treatments
Patient-derived xenograft (PDX) tumors were obtained from
the JAX PDX Resource. Tumor fragments were minced sepa-
rately and xenografted subcutaneously in an NSGTM mouse to
establish P1. Upon growth of the tumor fragment, the tumor
was harvested, minced, and xenografted in multiple mice to
establish P2 mice. All experiments were conducted on P2 or
higher mice that arose from engraftment from one of multiple
tumor fragments.
Expression analyses of early JAX PDX oncology models
were performed utilizing the ThermoFisher Scientific (for-
merly Affimetrix) GeneChip™ Human Genome U133 Plus
2.0 Array or GeneChip™ Human Gene 1.0 ST Array.51
Arrays from all microarray-assayed models were processed
together to generate normalized expression of all genes in
the two-microarray platforms. The affyPLM R package was
used, performing quantile normalization and no background
correction. The data were fitted to a simple model that treats
the log intensity as a sum of array effect, probe effect, and
residual. The array effect is the equivalent to the median
polished value produced by standard RMA analysis. The
gene expressions are provided as log2-transformed output
(normalized expression).
The differences between the normalized expression for
each gene in models TM00244 and TM00921 were calculated
to determine which genes displayed the greatest differential
expression between the two models. The gene list was then
exported into Ingenuity Pathway Analysis software that
revealed the effected pathways.
Xenograft studies
Human cancer cell lines, mentioned above, were xenografted
into NRGTM mice in the following way: Cells grown in flasks
were given fresh media the night before xenograftment and
seeded at 106 cells per mL. The next day, the cells were
washed twice with DPBS without calcium or magnesium
and resuspended to 1 – 2 × 108 cells per mL of DPBS at
room temperature and immediately injected via tail vein at
100 µL per mouse. The cells were given 7–10 days to fully
xenograft, after which tumor load in the blood was assessed
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via flow cytometry (FACSCaliber II) for human CD19+ cells
(Antibody cat no. 555413, BD Parmingen). Mice with similar
tumor loads were assigned to different treatment groups to
decrease bias and ensure more even tumor load across treat-
ments. Mice were treated as described in the Results section
for two weeks unless otherwise indicated. Upon euthanasia,
the spleen and the bone marrow were harvested and stained
for human CD19, and the cells were measured by flow cyto-
metry on the FACSCaliber II. Analysis of the flow data was
done by Flowjo version 8.8.7 (BD Pharmingen).
Metabolic measurements
Metabolic measurements were done on the Agilent Seahorse
XFe96 Analyzer using the Agilent XF cell energy phenotype
testing test kit according to the manufacturer’s instructions
(Cat. no. 103325–100). Measurements of intracellular ATP
were done using a commercially available fluorescence assay
from abcam (ab83355) using manufacturer’s recommenda-
tions. Measurements of free glucose were done using the
Glucose Assay kit from abcam (ab65333) using the colorimetric
methods according to manufacturer’s recommendations.
Treatment of the spontaneous tumor models with 2DG
SJL.CD8a-/- female mice were aged and monitored for signs of
tumor development weekly after reaching 6 months of age.
Tumors were evident by 7 to 12 months of age. Once tumors
had achieved clearly visible sizes, the mice were administered ad
libitum with 6 g/L of 2DG dissolved in drinking water. This
concentration of 2DG in the water supplied the mice with a daily
dose of approximately 900 mg/kg of 2DG. Mice were monitored
weekly to determine changes in tumor mass by palpation and
photographs, and overall tumor size changes, (same, smaller or
larger) compared with the preceding week of treatment, was
recorded. Treatments lasted for 11 weeks or until the tumors
returned and mice became too sick to continue in the study. The
treatment of one mouse was carried out to week 16 to determine
what, if any, side effects would occur with prolonged 2DG expo-
sure. This tumornever returned andno adverse effectswere noted.
Microct imaging and image reconstruction
MicroCT was performed using a high-speed in vivo µCT
scanner (Quantum GX, PerkinElmer, Hopkinton, MA,
USA). The images were acquired using a High Resolution
Scan mode with a 4-min scan time. The X-ray source was
set to a current of 88 µA, voltage of 90 kVp, and a 36 mm
FOV for a 50 µm voxel size. Animals were anesthetized with
2% isoflurane via nose cone while imaging. Administration of
anesthesia helped to minimize motion artifacts during scan-
ning. Animals were recovered in a clean box with pine shav-
ings placed on a 37°C heating pad until fully mobile and then
returned to their home cages.
The µCT imaging was visualized via 3D Viewer, existing
software within the Quantum GX system. The greyscale image
slices were selected on the basis of internal landmarks such as
ribs and spinal column so that images were generated in
approximately the same location within each animal. These
images were saved as JPEG files. Colored images were recon-
structed using Image J32 (V1.49) or the PerkinElmer 3D
Viewer application. Thresholds were used to visually deter-
mine optimal separation of the histogram into bone and soft
tissue. In this way, the lungs and tumor could be viewed
separately from the bone.
Gene expression analysis
Expression analyses of early JAX PDX oncology models
were performed utilizing the ThermoFisher Scientific (for-
merly Affimetrix) GeneChip™ Human Genome U133 Plus
2.0 Array or the GeneChip™ Human Gene 1.0 ST Array.
Arrays from all microarray-assayed models were processed
with the AffyPLM R package, using quantile normalization
and no background correction, and fitted to a simple model
that treats the log intensity as a sum of array effect, probe
effect, and residual. The array effect is the ‘summarized
expression’ that is equivalent to the median polished value
produced by standard RMA analysis. The differences
between the normalized expression for each gene in models
TM00244 and T
M00921 were calculated to identify the genes that showed
the greatest difference in expression between the models. The
gene list was then exported into Ingenuity Pathway Analysis
software, which revealed the effected pathways.
Statistics
All statistical parameters were calculated using EXCEL ver-
sion 15.4. Error bars are standard error of the mean (SEM)
and p-values are calculated by student t-test, unless indicated
otherwise.
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